Status:
COMPLETED
A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients
Lead Sponsor:
AstraZeneca
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
This is a multi-center, prospective, non-interventional study. The study will enroll about 1700 Chinese patients diagnosed as NSCLC and treated with osimertinib at least one dose. The objective of th...
Detailed Description
This is a multi-center, prospective, non-interventional study. The study will enroll about 1700 Chinese patients diagnosed as NSCLC and treated with osimertinib at least one dose. The investigator in ...
Eligibility Criteria
Inclusion
- Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures
- Patients histologically or cytologically diagnosed as NSCLC
- Eligible for osimertinib treatment per the judgement of the treating physician in clinical practice
- Received at least one dose of osimertinib
Exclusion
- • Enrollment in other on-going studies, which prohibit any participation in this non-interventional study
Key Trial Info
Start Date :
April 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 3 2023
Estimated Enrollment :
1700 Patients enrolled
Trial Details
Trial ID
NCT03485326
Start Date
April 21 2020
End Date
August 3 2023
Last Update
July 23 2024
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, China, 100142
2
Research Site
Chengde, China
3
Research Site
Chengdu, China, 610041
4
Research Site
Dingzhou, China